ID: ALA5266849

Max Phase: Preclinical

Molecular Formula: C22H21FN4O5S

Molecular Weight: 472.50

Representations

Canonical SMILES:  Cc1ccc(CS(=O)(=O)NC(=O)C2(F)CCN(c3nc4c(cc3C#N)C(=O)OC4)CC2)cc1

Standard InChI:  InChI=1S/C22H21FN4O5S/c1-14-2-4-15(5-3-14)13-33(30,31)26-21(29)22(23)6-8-27(9-7-22)19-16(11-24)10-17-18(25-19)12-32-20(17)28/h2-5,10H,6-9,12-13H2,1H3,(H,26,29)

Standard InChI Key:  GRNABBKPEMUKBK-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 472.50

Molecular Weight (Monoisotopic): 472.1217

AlogP: 1.89

#Rotatable Bonds: 5

Polar Surface Area: 129.46

Molecular Species: ACID

HBA: 8

HBD: 1

#RO5 Violations: 0

HBA (Lipinski): 9

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 3.56

CX Basic pKa: 0.62

CX LogP: 1.93

CX LogD: 0.99

Aromatic Rings: 2

Heavy Atoms: 33

QED Weighted: 0.65

Np Likeness Score: -0.94

References

1. Kong D, Xue T, Guo B, Cheng J, Liu S, Wei J, Lu Z, Liu H, Gong G, Lan T, Hu W, Hu W, Yang Y..  (2019)  Optimization of P2Y₁₂ Antagonist Ethyl 6-(4-((Benzylsulfonyl)carbamoyl)piperidin-1-yl)-5-cyano-2-methylnicotinate (AZD1283) Led to the Discovery of an Oral Antiplatelet Agent with Improved Druglike Properties.,  62  (6.0): [PMID:30843696] [10.1021/acs.jmedchem.8b01971]

Source

Source(1):

• Scientific Literature